TrialJournal for immunotherapy of cancer2022

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.

Scott S Tykodi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.